Molecular analysis of the Von Hippel-Lindau (VHL) gene in a family with non-syndromic pheochromocytoma: The importance of genetic testing

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 9, 2007, Pages 1463-1467

  Cruz, Juliana B ^a   Fernandes, Leonardo P S ^a   Clara, Sueli A ^a   Conde, Sandro J ^a   Perone, Denise ^a   Kopp, Peter ^b   Nogueira, Célia R ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Genetic testing; Mutation; Pheochromocytoma; Von Hippel Lindau disease

Indexed keywords

EID: 38849189979     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302007000900008     Document Type: Article

References (14)

1. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993;329(21):1531-8.
2. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346(19):1459-66.
3. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006;91(3):827-36.
4. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) genes in families from North America, Europe, and Japan. Hum Mutat 1996;8(4):348-57.
5. Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 1996;33(4):328-32.
6. Dahia PLM. Patogênese molecular do feocromocitoma. Arq Bras Endocrinol Metab 2001;45:507-17.
7. Weirich G, Klein B, Wöhl T, Engelhardt D, Brauch H. VHL2C phenotype in a German von Hippel-Lindau family with concurrent VHL germline mutations P81S and L188V. J Clin Endocrinol Metab 2002;87(11):5241-6.
8. Gimm O. Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx. Fam Cancer 2005;4(1):17-23.
9. Ivan M, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 2001;11(1):27-34.
10. Hes F, Zewald R, Peeters T, Sijmons R, Links T, Verheij J, et al. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum Genet 2000;106(4):425-31.
11. Hamrahian AH, Ioachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS, et al. Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005;90(2):871-7.
12. Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P. Increased expression of Cyclooxygenase-2 in Malignant Pheochromocytomas. J Clin Endocrinol Metab 2001;86:5615-9.
13. Gross DJ, Avishai N, Meiner V, Filon D, Zbar B, Abeliovich D. Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J Clin Endocrinol Metab 1996;81(1):147-9.
14. Jiménez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 2006;91(8):2851-8.